Scienture Holdings, Inc. has entered into a securities purchase agreement for the purchase of 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds for the offering are expected to be approximately $3.9 million before deducting placement agent fees and other offering expenses.
The offering is expected to close on August 15, 2025, subject to customary closing conditions.
Offering Details
3,225,000 shares of common stock at $1.20 per share.
Gross Proceeds
Approximately $3.9 million before deductions.
Closing Date
Expected to close on August 15, 2025.
- Scienture Holdings, Inc. aims to raise funds through a registered direct offering to support its operations and strategic initiatives in the pharmaceutical industry.
- The offering is a strategic move to enhance the company's financial position and propel the development and distribution of novel specialty products.
- Maxim Group LLC is serving as the sole placement agent for the offering, ensuring a streamlined process.
The successful completion of this registered direct offering is expected to strengthen Scienture Holdings, Inc.'s financial standing and support its mission of delivering value through innovative pharmaceutical products.